2024
Considerations when prescribing opioid agonist therapies for people living with HIV
Tarfa A, Lier A, Shenoi S, Springer S. Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review Of Clinical Pharmacology 2024, 17: 549-564. PMID: 38946101, PMCID: PMC11299801, DOI: 10.1080/17512433.2024.2375448.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDelayed-Action PreparationsDelivery of Health CareDrug InteractionsHealth Services AccessibilityHIV InfectionsHumansMethadoneNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPre-Exposure ProphylaxisUnited StatesConceptsOpioid agonist therapyOpioid use disorderAntiretroviral therapyAgonist therapyDiagnosed OUDOpioid use disorder managementUse disorderTreatment of opioid use disorderExtended-release naltrexonePotential drug interactionsOpioid use disorder treatmentPrescribed opioid agonist therapyLong-acting formulationPre-exposure prophylaxisOUD outcomesImprove HIV preventionIntersection of HIVOpioid antagonistHIV outcomesHIV epidemicOpioidHIVOpioid use disorder servicesPWHHIV preventionHIV Risk and Interest in Preexposure Prophylaxis in Justice-Involved Persons - Volume 30, Supplement—March 2024 - Emerging Infectious Diseases journal - CDC
Nijhawan A, Pulitzer Z, Torres B, Noreen N, Schultheis A, Frank C, Colon R, Brooks R, Proffitt R, Pankow J, Bennett A, Salyards M, Kuo I, Knight K, Springer S. HIV Risk and Interest in Preexposure Prophylaxis in Justice-Involved Persons - Volume 30, Supplement—March 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: s68-s74. PMID: 38561803, PMCID: PMC10986824, DOI: 10.3201/eid3013.230739.Peer-Reviewed Original ResearchMeSH KeywordsFemaleHispanic or LatinoHIV InfectionsHomosexuality, MaleHumansMalePre-Exposure ProphylaxisRisk FactorsConceptsHIV riskAssess HIV risk factorsPreexposure prophylaxisPartners of unknown HIV statusMobile health unitReport injection drug useUnknown HIV statusPerceived HIV riskRisk factorsHIV risk factorsRandomized controlled trialsPatient navigationPrEP indicationsInjection drug useHealth unitsJustice-involved personsHIV medicationsHIV statusCondomless sexPrEPEducational effortsDrug useHIVRiskPersons
2022
Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons
Springer SA, Nijhawan AE, Knight K, Kuo I, Di Paola A, Schlossberg E, Frank CA, Sanchez M, Pankow J, Proffitt RP, Lehman W, Pulitzer Z, Thompson K, Violette S, Harding KK. Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons. BMC Infectious Diseases 2022, 22: 380. PMID: 35428213, PMCID: PMC9013109, DOI: 10.1186/s12879-022-07354-x.Peer-Reviewed Original ResearchConceptsJustice-involved individualsAntiretroviral treatmentHIV preventionUse disordersStudy participantsStimulant useSubstance use disorder servicesCommunity-based HIVPost-release interventionsPrimary implementation outcomeHIV viral loadPre-exposure prophylaxisOpioid use disorderTreatment of HIVHIV risk behaviorsRisk of HIVSubstance use disordersHigh-risk communitiesHybrid type 1Justice-involved personsHCV testingLinkage interventionHIV careSecondary outcomesART adherence
2021
Feasibility of a community‐based delivery model for HIV pre‐exposure prophylaxis among bar patrons in rural South Africa
Grammatico MA, Moll AP, Choi K, Springer SA, Shenoi SV. Feasibility of a community‐based delivery model for HIV pre‐exposure prophylaxis among bar patrons in rural South Africa. Journal Of The International AIDS Society 2021, 24: e25848. PMID: 34826363, PMCID: PMC8625837, DOI: 10.1002/jia2.25848.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnti-HIV AgentsFeasibility StudiesHIV InfectionsHumansMaleMedication AdherencePre-Exposure ProphylaxisSouth AfricaConceptsPre-exposure prophylaxisAlcohol Use Disorders Identification TestLargest HIV epidemicCommunity-based delivery modelPrEP uptakeHIV testingOdds ratioOral tenofovir disoproxil fumarate/emtricitabineTenofovir disoproxil fumarate/emtricitabineRural South AfricaHazardous drinkingDisoproxil fumarate/emtricitabineHIV pre-exposure prophylaxisUptake of PrEPHIV care cascadeRapid HIV testingAdjusted odds ratioYoung menRural KwaZulu-Natal ProvinceAlcohol use disorderSexual risk behaviorsDisorders Identification TestBar patronsPrEP deliveryPrEP initiators
2020
Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose.
Strathdee SA, Kuo I, El-Bassel N, Hodder S, Smith LR, Springer SA. Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose. AIDS 2020, 34: 1997-2005. PMID: 32826391, PMCID: PMC7606503, DOI: 10.1097/qad.0000000000002673.Peer-Reviewed Original ResearchMeSH KeywordsContinuity of Patient CareDisease OutbreaksHIV InfectionsHumansPre-Exposure ProphylaxisSubstance Abuse, IntravenousSubstance-Related DisordersUnited StatesConceptsHIV outbreakRecent HIV outbreaksEpidemiology of HIVEvidence-based interventionsOpioid disordersHIV infectionTreatment cascadeEvidence-based responsesHIV epidemicOpioid epidemicHIV preventionPrescription opiatesHIVPWIDSynthetic opioidsDrugsPublic healthInfectionPreventionHigher proportionUnited StatesEpidemicOutbreakEditorial reviewRelentless cycle